Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Ecopipam (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- Sponsors Emalex Biosciences; Psyadon Pharmaceuticals
- 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
- 04 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 04 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2019.